EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort

Khaled Ezzedine iD, Julien Seneschal iD, Audrey Da Silva, Nathalie Préaubert, Anne Lamblin, Carine Delattre, Corinne Emery, Camille Nevoret, Jonathan Finzi, Stéphane Bouée iD, Thierry Passeron iD

Journal of the European Academy of Dermatology and Venereology · 2023-11 · 37 (11) · 2249-2258

DOI: 10.1111/jdv.19447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 31.08.2023. Verfasst von Khaled Ezzedine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France. Hauptthemen laut MEDLINE: Vitiligo, Alopecia Areata. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Corporation, Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitiligo is a chronic autoimmune disease resulting in skin depigmentation.

Objectives

This study assessed the prevalence, disease burden and treatment of vitiligo in France.

Methods

VIOLIN was a cross‐sectional study nested in the national CONSTANCES cohort, which consists of randomly selected adults aged 18–69 years in France. In VIOLIN, longitudinal data were collected prospectively from 158,898 participants during 2012–2018 and linked to the National Health Data System (SNDS), a healthcare utilization database. Patients with physician‐diagnosed vitiligo were matched (1:3) with control participants based on age, sex, geographic region, year of inclusion and skin phototype. Patients completed a questionnaire in 2022 to collect disease characteristics, disease burden and quality‐of‐life (QoL) data.

Results

Vitiligo prevalence was 0.71% (681/95,597) in 2018. The mean age in the vitiligo population was 51.2 years; 51.4% were women. Most patients (63%) were diagnosed before age 30 years, mainly by dermatologists (83.5%). Most patients (81.1%) had visible lesions (i.e. on face, hands). Vitiligo was limited to 5% BSA involvement or visible lesions, particularly with ≥10% facial involvement. Vitiligo‐specific instruments (i.e. Vitiligo Impact Patient scale and Vitiligo‐specific QoL instrument) were more sensitive to QoL differences among subgroups versus general skin instruments, and generic instruments were least sensitive. Most patients (83.8%) did not receive any prescribed treatment.

Conclusions

Patients with vitiligo in France have a high disease burden, particularly those with visible lesions or higher BSA involvement. Most patients are not receiving treatment, highlighting the need for new effective treatments and patient/physician education.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoAlopecia AreataAdultHumansFemaleMiddle AgedMaleQuality of LifeCross-Sectional StudiesCost of Illness

Autor:innen und Institutionen

  • Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France.
  • Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint André, CNRS, UMR-5164, ImmunoConcEpT, Bordeaux, France.
  • Incyte Biosciences France, Boulogne-Billancourt, France.
  • Medconsult, Boulogne-Billancourt, France.
  • Association Française du Vitiligo, Paris, France.
  • Incyte Biosciences International Sàrl, Morges, Switzerland.

ORCID-Profile: Khaled Ezzedine, Julien Seneschal, Stéphane Bouée, Thierry Passeron

Förderung

  • Incyte Corporation
  • Incyte

Zitieren

APA

Ezzedine, K., Seneschal, J., Da Silva, A., Préaubert, N., Lamblin, A., Delattre, C., Emery, C., Nevoret, C., Finzi, J., Bouée, S., & Passeron, T. (2023). Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort. Journal of the European Academy of Dermatology and Venereology, 37(11), 2249-2258. https://doi.org/10.1111/jdv.19447

Vancouver

Ezzedine K, Seneschal J, Da Silva A, Préaubert N, Lamblin A, Delattre C, et al. Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort. Journal of the European Academy of Dermatology and Venereology. 2023;37(11):2249-2258. doi:10.1111/jdv.19447

BibTeX
@article{Ezzedine2023,
  author = {Ezzedine, Khaled and Seneschal, Julien and Da Silva, Audrey and Préaubert, Nathalie and Lamblin, Anne and Delattre, Carine and Emery, Corinne and Nevoret, Camille and Finzi, Jonathan and Bouée, Stéphane and Passeron, Thierry},
  title = {Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {11},
  pages = {2249--2258},
  doi = {10.1111/jdv.19447}
}
Kostenlos starten →